These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 29981924

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
    Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ.
    J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Second- and third-generation ALK inhibitors for non-small cell lung cancer.
    Wu J, Savooji J, Liu D.
    J Hematol Oncol; 2016 Mar 08; 9():19. PubMed ID: 26951079
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A.
    Expert Rev Clin Pharmacol; 2016 Aug 08; 9(8):1005-13. PubMed ID: 27232673
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
    Passaro A, Prelaj A, Pochesci A, Spitaleri G, Rossi G, Del Signore E, Catania C, de Marinis F.
    Drugs Today (Barc); 2017 Aug 08; 53(8):435-446. PubMed ID: 29119148
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. ALK-rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib.
    Song L, Zeng L, Zhang Y.
    Thorac Cancer; 2022 Apr 08; 13(7):1095-1097. PubMed ID: 35150066
    [No Abstract] [Full Text] [Related]

  • 15. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V, Ou SH.
    Expert Opin Drug Saf; 2017 Apr 08; 16(4):509-514. PubMed ID: 28276856
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G, Seto T, Takenoyama M, Ichinose Y.
    Cancer Metastasis Rev; 2015 Dec 08; 34(4):797-805. PubMed ID: 26342831
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.
    Srinivasamaharaj S, Salame BK, Rios-Perez J, Kloecker G, Perez CA.
    Expert Rev Anticancer Ther; 2016 Dec 08; 16(12):1227-1233. PubMed ID: 27744726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.